Заявка Altay Therapeutics в YC

Winter 2020Active

Altay Therapeutics прошел Y Combinator в потоке Winter 2020 как компания из сферы Healthcare. Ниже: чем занимается компания, кто ее основал, и ее заявка в YC, реконструированная вопрос за вопросом в реальной форме YC.

Поток YC: Winter 2020
Сфера: HealthcareTherapeutics
Размер команды: 6
Статус: Active
Запущено: 2020

Фаундеры

Ali OzesFounder
Osman OzesFounder

Чем занимается Altay Therapeutics

Altay develops small molecule drugs to treat chronic liver diseases like liver fibrosis and liver cancer. Our co-founder Dr. Osman Ozes, led the first drug development program for Esbriet (Pirfenidone), resulting in the first FDA approved therapy for lung fibrosis. Esbriet is now a $1 billion/year drug and has already made over $6 billion in revenue. With a team that has over 70+ years of small molecule drug development experience, we intend to do the same with chronic liver diseases, which affects over 20 million Americans and represents a market size of over $30 billion. We know we are well positioned for success because we have shown excellent pre-clinical mouse data in several liver fibrosis models using our novel small molecule. We demonstrate a reduction in fibrosis with our drug, but more significantly, we show a reversal in fibrotic tissue back to normal tissue. With our current developmental strategy, we hope to have a clinic-ready compound by the end of 2021 and be in phase I clinical trials by mid of 2022.

Заявка Altay Therapeutics в YC, реконструирована

Заявка Y Combinator

Altay Therapeutics, батч Winter 2020. Реальные вопросы из анкеты, ответы из публичных данных.

Founders2
Company7
Progress7
Idea4
Equity3
Curious2
Batch Preference1

Company

Company name

Altay Therapeutics

Describe what your company does in 50 characters or less.

Small molecule therapies for liver disease

What is your company going to make? Please describe your product and what it does or will do.

We develop small molecule drugs that target transcription pathways to treat chronic liver diseases like fibrosis and cancer. Our lead compound has shown in mouse models not just reduction but reversal of liver fibrosis, aiming for a clinic-ready drug by end of 2021 and phase I trials mid-2022.

Where do you live now, and where would the company be based after YC?

We live and work in San Francisco and South San Francisco, CA, which will remain our base after YC.

Explain your decision regarding location.

We chose to base the company in San Francisco because that's where the biotech innovation ecosystem and our team are. It keeps us close to partners, investors, and talent relevant to small molecule therapeutic development.

21 еще ответ в полной заявке

Founders, Progress, Idea, Equity, Curious, Batch Preference находятся в полной версии. Создайте бесплатную учетную запись, чтобы открыть ее в YC Insights, рядом с каждым другим потоком YC.

Смотреть полную заявку

Часто задаваемые вопросы

Это реальная заявка Altay Therapeutics в YC?

Нет. Y Combinator держит поданные заявки в приватности. Это реконструкция: реальные вопросы формы YC, ответы на которые основаны на публичных данных Altay Therapeutics (заметки о запуске, бэкграунд фаундеров, описание продукта). Это показывает, как компания вроде Altay Therapeutics представила бы себя YC, а не текст, который они подали.